Skip to main content

Advertisement

SpringerLink
Log in

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma

  • Short Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Purpose: This randomized phase II, parallel-design study evaluated preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with resectable adenocarcinoma of the esophagus that were stage II or greater. The objectives of the trial were to determine pathologic complete response rate (pCR), overall response rate, progression-free survival, pattern of disease relapse, and two-year and overall survival.

Patients and Methods: Preoperative staging included computed tomography, endoscopic ultrasound, and, when feasible, laparoscopy. Eligible patients were randomized to preoperative prinomastat or placebo, plus continuous infusion 5-FU, cisplatin, paclitaxel, and concurrent radiotherapy. Esophagectomy was performed on day 71. Adjuvant paclitaxel and prinomastat were available to all study patients.

Results: Between August 2000 and June 2001, 15 of a planned 78 patients were randomized into the trial. One patient after randomization withdrew consent. Fourteen patients, 7 in each arm, completed preoperative treatment and surgery. pCR was achieved in 5 patients; 1/ 7 prinomastat and 4/ 7 placebo. Disease improvement was achieved in 7 patients; 5 /7 prinomastat and 2 /7 placebo. At a median follow-up of 28 months, 7 patients (2 prinomastat, 5 placebo) are alive with no evidence of disease. The primary prinomastat related toxicity was moderate to severe musculoskeletal toxicity interfering with daily function. This toxicity was managed with treatment rest, dose reduction, or discontinuation. Five patients (3 prinomastat and 2 placebo) had life-threatening thrombo-embolic events, which led to early evaluation of safety and efficacy, and subsequent termination of the study.

Conclusions: All patients, regardless of treatment arm, were able to successfully undergo neoadjuvant combined modality therapy and esophagectomy. However, early closure of the study due to unexpected thrombo-embolic events precluded any conclusions regarding clinical activity of prinomastat in locally advanced esophageal cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Cukingnan RA, Carey JS (1978) Carcinoma of the esophagus. Ann Thorac Surg 26:274–286

    Article  PubMed  CAS  Google Scholar 

  2. Ellis FH Jr (1983) Carcinoma of the esophagus. CA 33:264–281

    PubMed  Google Scholar 

  3. DeMeester TR, Barlow A (1988) Surgery and current management for cancer of the esophagus and cardia. Curr Probl Cancer 12(5):243–328

    Article  PubMed  CAS  Google Scholar 

  4. Skinner DBy (1984) Surgery for esophageal cancer. Sem Oncol 11:136–143

    CAS  Google Scholar 

  5. Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayode K, Forastiere AA (2000) Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18:868– 876

    PubMed  CAS  Google Scholar 

  6. Forastiere AA, Heitmiller RF, Lee DJ, Zahurak M, Abrams R, Kleinberg L, Watkins S, Yeo CJ, Lillemoe KD, Sitzmann JV, Sharfman W (1997) Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 3:144–152

    PubMed  CAS  Google Scholar 

  7. Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA (2003) Mature survival results with preoperative cisplatin, protracted infusion 5-fluoruracil and 44-Gy radiotherapy for esophageal cancer. Int J Radiation Oncology Biol Phys 56:328–334

    Article  CAS  Google Scholar 

  8. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197–250

    PubMed  CAS  Google Scholar 

  9. Cottam DW, Rees RC (1993) Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis. Int J Oncol 2:861–872

    CAS  Google Scholar 

  10. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U (2001) Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. British Journal of Cancer 85:383–392

    Article  PubMed  CAS  Google Scholar 

  11. Murphy G, Cockett MI, Ward RV, Docherty AJ (1991) Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1, and –2 and punctuated metalloproteinase (PUMP). Biochem J 277:277–279

    PubMed  CAS  Google Scholar 

  12. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE (1998) Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185:256–261

    Article  PubMed  CAS  Google Scholar 

  13. Shalinksy DR, Brekken J, Robinson SR, Varki NV, Daniels R, Bender S, Zook S, Kolis S, Khelemsaaya N, Gabriel L, Wood AW, Webber S and Appelt K (1998) Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivo by orally administered AG3440, a novel matrix metalloproteinase (MMP) inhibitor. Proc Amer Assoc Cancer Res 39:2059

    Google Scholar 

  14. Johnston MR, Mullen JBM, Pagura M, Appelt K and Shalinsky DR (1998) AG3340, a novel matrix metallloproteinase (MMP) inhibitor, decreases growth and metastases of orthotopic human lung cancer in a nude rat preclinical model system. Proc Amer. Assoc Cancer Res 39:2061

    Google Scholar 

  15. Heath EI, Grochow LB (2000) Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 59:1–13

    Article  Google Scholar 

  16. Johnston MR, Mullen JM, Pagura M, Brekken J, Aou H, Shalinsky DR (1999) AG3340 and carboplatin increase survival in an orthotopic nude rat model of primary and metastatic human lung cancer. Proc Amer Assoc. Cancer Res 40:1946

    Google Scholar 

  17. Chambers AF (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–70

    Article  PubMed  CAS  Google Scholar 

  18. Fortunato SJ, Menon R (2002) Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. J Assisted Reprod Genet 19:483–6

    Article  Google Scholar 

  19. Heath EI, Talamini MA, Kaufman H, Wheeler J, Heitmiller RF, Olukayode K, Forastiere AA (2000) The role of laparoscopy in preoperative staging of esophageal cancer. Surgical Endoscopy 14:495– 499

    Article  PubMed  CAS  Google Scholar 

  20. Fleming ID (ed) (1997) AJCC cancer staging manual, edn. 5. Lippincott-Raven, Philadelphia, PA

  21. Simon R (1989) Optimal two stage designs for phase II clinical trials. Control Clin Trials 10:1

    Article  PubMed  CAS  Google Scholar 

  22. Behrendt CE, Ruiz RB (2003) Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 90:734–737

    PubMed  CAS  Google Scholar 

  23. Sutherland DE, Weitz IC, Liebman HA (2003) Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis and treatment. American Journal of Hematology 72:43–52

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI

    Elisabeth I. Heath

  2. Departments of Oncology, Surgery, Medicine and Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

    Lawrence Kleinberg, Stephen C. Yang, Richard F. Heitmiller, Marcia I. Canto, Elizabeth Montgomery, Nancy Tsottles & Arlene A. Forastiere

  3. Department of Internal Medicine, Surgery and Therapeutic Radiology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT

    Barbara A. Burtness, Ronald R. Salem, Jonathan P. S. Knisely & Mark Topazian

  4. Pfizer Global Research and Development – La Jolla Laboratories, La Jolla, CA

    Yazdi Pithavala, Bridget Rohmiller & Mary Collier

Authors
  1. Elisabeth I. Heath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara A. Burtness
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Kleinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald R. Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephen C. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard F. Heitmiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marcia I. Canto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jonathan P. S. Knisely
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mark Topazian
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Elizabeth Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nancy Tsottles
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yazdi Pithavala
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Bridget Rohmiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mary Collier
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Arlene A. Forastiere
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth I. Heath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heath, E.I., Burtness, B.A., Kleinberg, L. et al. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 24, 135–140 (2006). https://doi.org/10.1007/s10637-006-5934-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-006-5934-5

Keywords

Search

Navigation